284 related articles for article (PubMed ID: 31205499)
1. New frontiers in the medical management of gastrointestinal stromal tumours.
Mazzocca A; Napolitano A; Silletta M; Spalato Ceruso M; Santini D; Tonini G; Vincenzi B
Ther Adv Med Oncol; 2019; 11():1758835919841946. PubMed ID: 31205499
[TBL] [Abstract][Full Text] [Related]
2. Ripretinib for the treatment of advanced gastrointestinal stromal tumor.
Zalcberg JR
Therap Adv Gastroenterol; 2021; 14():17562848211008177. PubMed ID: 33948116
[TBL] [Abstract][Full Text] [Related]
3. Fourth-line rescue treatment ripretinib of advanced small intestine gastrointestinal stromal tumors who achieved partial response: a case report.
Liu B; Kou Y
J Gastrointest Oncol; 2022 Jun; 13(3):1505-1513. PubMed ID: 35837161
[TBL] [Abstract][Full Text] [Related]
4. The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours.
Foo T; Goldstein D; Segelov E; Shapiro J; Pavlakis N; Desai J; Yip D; Zalcberg J; Price TJ; Nagrial A; Chantrill L; Burge M; Karapetis CS; Tebbutt N; Roy AC
Target Oncol; 2022 Mar; 17(2):95-110. PubMed ID: 35290591
[TBL] [Abstract][Full Text] [Related]
5. Combination of Type I and II tyrosine kinase inhibitors-avapritinib and sunitinib-in refractory gastrointestinal stromal tumor after failure to multi-line therapy: a case report.
Guo X; Huang S; Shi Y; Guan Z; Chen S; Feng Y; Xia Y; Zhang X
Ann Transl Med; 2022 Sep; 10(18):1026. PubMed ID: 36267752
[TBL] [Abstract][Full Text] [Related]
6. Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor.
Bauer S; George S; von Mehren M; Heinrich MC
Front Oncol; 2021; 11():672500. PubMed ID: 34322383
[TBL] [Abstract][Full Text] [Related]
7. New treatment strategies for advanced-stage gastrointestinal stromal tumours.
Klug LR; Khosroyani HM; Kent JD; Heinrich MC
Nat Rev Clin Oncol; 2022 May; 19(5):328-341. PubMed ID: 35217782
[TBL] [Abstract][Full Text] [Related]
8. Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors.
Van Looy T; Gebreyohannes YK; Wozniak A; Cornillie J; Wellens J; Li H; Vanleeuw U; Floris G; Debiec-Rychter M; Sciot R; Schöffski P
Clin Sarcoma Res; 2014; 4():10. PubMed ID: 25132955
[TBL] [Abstract][Full Text] [Related]
9. Revolutions in treatment options in gastrointestinal stromal tumours (GISTs): the latest updates.
Farag S; Smith MJ; Fotiadis N; Constantinidou A; Jones RL
Curr Treat Options Oncol; 2020 May; 21(7):55. PubMed ID: 32462367
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
Nishida T; Doi T; Naito Y
Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
[TBL] [Abstract][Full Text] [Related]
11. Precision medicine in gastrointestinal stromal tumors.
Florou V; Trent JC; Wilky BA
Discov Med; 2019; 28(155):267-276. PubMed ID: 32053767
[TBL] [Abstract][Full Text] [Related]
12. Surgery for metastatic gastrointestinal stromal tumor: to whom and how to?
Kikuchi H; Hiramatsu Y; Kamiya K; Morita Y; Sakaguchi T; Konno H; Takeuchi H
Transl Gastroenterol Hepatol; 2018; 3():14. PubMed ID: 29682621
[TBL] [Abstract][Full Text] [Related]
13. Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward.
Lostes-Bardaji MJ; García-Illescas D; Valverde C; Serrano C
Ther Adv Med Oncol; 2021; 13():1758835920986498. PubMed ID: 33473249
[TBL] [Abstract][Full Text] [Related]
14. Ripretinib for the treatment of advanced, imatinib-resistant gastrointestinal stromal tumors.
Liu WZ; Du YQ; Shen Q; Tao KX; Zhang P
J Dig Dis; 2023 Sep; ():. PubMed ID: 37706279
[TBL] [Abstract][Full Text] [Related]
15. Current research and treatment for gastrointestinal stromal tumors.
Lim KT; Tan KY
World J Gastroenterol; 2017 Jul; 23(27):4856-4866. PubMed ID: 28785140
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
17. Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors.
Gebreyohannes YK; Wozniak A; Zhai ME; Wellens J; Cornillie J; Vanleeuw U; Evans E; Gardino AK; Lengauer C; Debiec-Rychter M; Sciot R; Schöffski P
Clin Cancer Res; 2019 Jan; 25(2):609-618. PubMed ID: 30274985
[TBL] [Abstract][Full Text] [Related]
18. Progression of the tumor in a patient with a gastrointestinal stromal tumor with the
An Z; Tan M; Xia Y; Li Y; Fan L; Zhao Q; Zhang Z; Tan B; Liu Y; Ma Z; Wang D; Zhao X
J Gastrointest Oncol; 2022 Oct; 13(5):2620-2625. PubMed ID: 36388657
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Systemic Treatment Options for Gastrointestinal Stromal Tumours.
Golčić M; Jones RL; Huang P; Napolitano A
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627109
[TBL] [Abstract][Full Text] [Related]
20. Establishment and characterization of patient-derived xenograft models of gastrointestinal stromal tumor resistant to standard tyrosine kinase inhibitors.
Na YS; Ryu MH; Yoo C; Lee JK; Park JM; Lee CW; Lee SY; Shin YK; Ku JL; Ahn SM; Kang YK
Oncotarget; 2017 Sep; 8(44):76712-76721. PubMed ID: 29100343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]